Patents Examined by Zinna Northington Davis
-
Patent number: 12042495Abstract: One embodiment of the disclosure is a compound represented by Formula I or a pharmaceutically acceptable salt thereof. The variables in Formula I are defined herein. Compounds of Formula I are selective MAP4K1 inhibitors, which can be used to treat a diseases or disorders in a subject that benefits from control of MAP4K1 activity.Type: GrantFiled: October 18, 2022Date of Patent: July 23, 2024Assignee: Blueprint Medicines CorporationInventors: Jason D. Brubaker, Michael J. Burke, Joshua T. Close, Thomas A. Dineen, Joseph L. Kim, Chandrasekhar V. Miduturu, Emanuele Perola
-
Patent number: 12036210Abstract: There is herein provided a compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein the ring containing Q1 to Q5, and the groups R1, R2 and R3, have meanings as provided in the description.Type: GrantFiled: January 13, 2022Date of Patent: July 16, 2024Assignee: ATROGI ABInventors: Benjamin Pelcman, Tore Bengtsson
-
Patent number: 12030854Abstract: The invention provides a method for producing a dichloro addition product of an aliphatic olefin by photocatalysis under visible light. The method includes reacting an aliphatic olefin as a substrate with hydrochloric acid as a chlorine source in an organic solvent under visible light irradiation in the presence of copper chloride with visible light absorption ability as a catalyst, to obtain the dichloro addition product of the aliphatic olefin, wherein the reaction is carried out under an oxygen-containing atmosphere, the aliphatic olefin comprises a carbon-carbon double bond and a C9-C15 aliphatic chain connected to the carbon-carbon double bond by a covalent bond. In the invention, visible light is used to provide the energy and a transition metal chloride with visible light absorption ability is used to undergo light-induced electron transfer from chloride with a reaction substrate, thereby initiating an addition reaction to obtain a dichloro addition product.Type: GrantFiled: July 21, 2020Date of Patent: July 9, 2024Assignee: SOOCHOW UNIVERSITYInventors: Xiaobing Wan, Pengcheng Lian, Wenhao Long, Jingjing Li, Yonggao Zheng
-
Patent number: 12030871Abstract: Compounds of formula (I) wherein R1, R2, R3, R4, R5, R23, R24, L, A and B are as defined in claim 1, or pharmaceutically acceptable salts thereof are disclosed. The compounds of formula (I) possess utility as cytochrome P450 monooxygenase 11A1 (CYP11A1) inhibitors. The compounds are useful as medicaments in the treatment of steroid receptor, particularly androgen receptor, dependent diseases and conditions, such as prostate cancer.Type: GrantFiled: July 6, 2021Date of Patent: July 9, 2024Assignee: ORION CORPORATIONInventors: David Din Belle, Mikko Mäkelä, Mikko Passiniemi, Pekka Pietikäinen, Petteri Rummakko, Eija Tiainen, Matti Vaismaa, Gerd Wohlfahrt
-
Patent number: 12024512Abstract: Improving the solubility of an organic compound. A cocrystal of (1) 6-ethyl-N-[1-(hydroxyacetyl)piperidin-4-yl]-1-methyl-4-oxo-5-(2-oxo-2-phenylethyl)-3-(2,2,2-trifluoroethoxy)-4,5-dihydro-1H-pyrrolo[3,2-c]pyridine-2-carboxamide and (2) L-malic acid or L-tartaric acid.Type: GrantFiled: December 22, 2020Date of Patent: July 2, 2024Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Kentaro Iwata, Yukihiro Ikeda
-
Patent number: 11999697Abstract: Disclosed herein are compounds, 3,4,6,8-substituted-2-([1,1?-biphenyl]-4-yl)quinoline analogs, that are inhibitors of dihydroorotate dehydrogenase (DHODH) with improved pharmacokinetic properties. The disclosed compounds can be used in the treatment of a variety of disorders and diseases in which inhibition of DHODH can be clinically useful, including cancer, such as a hematological cancer, including acute myeloid leukemia (AML); graft-versus-host-diseases; autoimmune disorders; and disorders associated with T-cell proliferation. The disclosed compounds can demonstrate flip-flop kinetics when administered orally, i.e., pharmacokinetics in which the rate of absorption, rather than the rate of elimination, dominates the pharmacokinetics. The disclosed compounds can demonstrate a sustained pharmacokinetic profile instead of an immediate release profile. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.Type: GrantFiled: November 10, 2021Date of Patent: June 4, 2024Assignees: OHIO STATE INNOVATION FOUNDATION, HENDRIX COLLEGEInventors: John C. Byrd, Thomas E. Goodwin, Ola Elgamal, Erin Hertlein, Mouad Abdulrahim, Chad E. Bennett, Sandip Madhukar Vibhute
-
Patent number: 11986471Abstract: Compounds are provided according to Formula (I): and pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof; wherein X1, X2, X3, X4, Y, A, L1, L2, R1, R2, R5, m and n are as defined herein. Compounds of the present invention are contemplated useful for the prevention and treatment of a variety of conditions.Type: GrantFiled: June 3, 2021Date of Patent: May 21, 2024Assignee: Tango Therapeutics, Inc.Inventors: Kevin M. Cottrell, John P. Maxwell, Douglas A. Whittington
-
Patent number: 11981653Abstract: The present application discloses a synthesis method of chiral nicotine from nicotinate and ?-butyrolactone, including the following steps: Step S1: performing condensation under an alkaline condition, and performing ring opening reaction with hydrochloric acid; Step S2: reacting with (+)—B-diisopinocampheyl chloroborane to produce a chiral hydroxyl group; Step S3: performing a chlorination reaction; and Step S4: performing cyclization under an alkaline condition to obtain the chiral nicotine. In the present application, nicotinate and ?-butyrolactone, both cheap and readily available, are used as raw materials, so as to reduce the production cost of (S)-nicotine. (+)—B-diisopinocampheyl chloroborane is used to reduce a carbonyl group of an intermediate to obtain a target chiral center.Type: GrantFiled: April 11, 2022Date of Patent: May 14, 2024Assignee: SHENZHEN ZINWI BIO-TECH CO., LTDInventors: Jun Zou, Yang Zou, Meisen Liu, Weixian Luo
-
Patent number: 11980872Abstract: Epoxidation methods and catalyst are described herein. The epoxidation catalysts generally include a metal component including silver and a support material including kaolinite, wherein the epoxidation catalyst includes less than 55 wt. % metal component.Type: GrantFiled: July 17, 2020Date of Patent: May 14, 2024Assignee: Lyondell Chemical Technology, L.P.Inventors: Sandor Nagy, Barbara Kimmich
-
Patent number: 11981638Abstract: Disclosed are a phenyl amino sodium propionate derivative, a preparation method therefor and an application thereof. Specifically, disclosed are sodium 3-(4-(2-(9H-carbazole-9-yl)ethoxy)phenyl)-2-((2-(4-(4-(2-sodium forrnate-2-((2-(4-fluorobenzoyl)phenyl)amino)ethyl)phenoxy)benzoyl)phenyl)amino)propionate, a preparation method therefor and the use thereof for quality control of a bulk drug or formulation of Chiglitazar or a derivative thereof. Particularly, the compound can be used as a control substance or standard substance for the detection of impurities/related substances in Chiglitazar or a sodium salt drug thereof.Type: GrantFiled: April 29, 2019Date of Patent: May 14, 2024Assignee: SHENZHEN CHIPSCREEN BIOSCIENCES CO., LTD.Inventors: Xianping Lu, Zhibin Li, Xianghui Wang, Weijun Gao, Xingyu Deng
-
Patent number: 11970731Abstract: The invention relates to compounds, methods and compositions for improving on nucleic acid polymerization, including DNA replication by in vitro primer extension to generate, for example, polymers for nanopore-based single molecule sequencing of a DNA template. A nucleic acid polymerase reaction composition is provided with polymerization enhancement moieties, which allows enhanced DNA polymerase activity with nucleotide analogs, resulting in improved length of primer extension products for sequencing applications.Type: GrantFiled: December 27, 2018Date of Patent: April 30, 2024Assignee: Roche Sequencing Solutions, Inc.Inventors: Mark Stamatios Kokoris, John Tabone, Melud Nabavi, Aaron Jacobs, Dylan O'Connell, Drew Goodman, Lacey Merrill, Jagadeeswaran Chandrasekar, Kendall Berg, Samantha Vellucci, Jessica Vellucci
-
Patent number: 11957667Abstract: Methods of treating a disease caused by a positive strand RNA virus. The methods include administering to a subject in need thereof an effective amount of a compound of Formula I or Formula II.Type: GrantFiled: July 7, 2021Date of Patent: April 16, 2024Assignee: National Health Research InstitutesInventors: Shiow-Ju Lee, Cheng-Wei Yang, Yue-Zhi Lee, Hsing-Yu Hsu
-
Patent number: 11957687Abstract: The disclosure relates to compounds and pharmaceutical compositions capable of modulating the hydroxysteroid 17-beta dehydrogenase (HSD17B) family member proteins including inhibiting the HSD17B member proteins, e.g. HSD17B13. The disclosure further relates to methods of treating liver diseases, disorders, or conditions with the compounds and pharmaceutical compositions disclosed herein, in which the HSD17B family member protein plays a role.Type: GrantFiled: July 1, 2020Date of Patent: April 16, 2024Assignee: REGENERON PHARMACEUTICALS, INC.Inventor: Joseph Vacca
-
Patent number: 11952365Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 8, 2021Date of Patent: April 9, 2024Assignees: Aligos Therapeutics, Inc., Katholieke Universiteit LeuvenInventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Leonid Beigelman, Vladimir Serebryany, Antitsa Dimitrova Stoycheva, Dorothée Alice Marie-Eve Bardiot, Sandro Boland, Arnaud Didier Marie Marchand
-
Patent number: 11944606Abstract: Azaindole compounds and their use as inhibitors of HPK1 are described. The compounds are useful in treating HPK1-dependent disorders and enhancing an immune response. Also described are methods of inhibiting HPK1, methods of treating HPK1-dependent disorders, methods for enhancing an immune response, and methods for preparing the azaindole compounds.Type: GrantFiled: February 17, 2021Date of Patent: April 2, 2024Assignee: Genentech, Inc.Inventors: Timothy Heffron, Sushant Malhotra, BinQing Wei, Bryan Chan, Lewis Gazzard, Emanuela Gancia, Michael Lainchbury, Andrew Madin, Eileen Seward, Yonghan Hu
-
Patent number: 11945782Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunctions; thus, there is also utility for small organic compound ligands and can raise LDL levels.Type: GrantFiled: November 13, 2020Date of Patent: April 2, 2024Assignee: SRX Cardio, LLCInventors: Thomas E. Barta, Jonathan William Bourne, Kyle D. Monroe, Michael M. Muehlemann, Anjali Pandey, Simeon Bowers
-
Patent number: 11945790Abstract: Compounds and compositions useful in methods of treating, ameliorating, or inhibiting the development of an autoimmune disease by modulating the T cell response to antigenic peptide or fragments of antigenic peptides presented by the major histocompatibility (MHC) class II molecule, DQ2.Type: GrantFiled: December 21, 2021Date of Patent: April 2, 2024Assignee: ImmunoMolecular Therapeutics, Inc.Inventors: Robert B. Perni, Ryan Schutte, James M. Siedlecki
-
Patent number: 11939307Abstract: Disclosed are a benzyl piperazine compound, a preparation method there for and an application thereof in an antivirus. The benzyl piperazine compound has a structure represented by the following general formula(I). It is proven by experiments that the benzyl piperazine compound not only has significant antiviral activity, but also has the advantages of low cytotoxicity, a high selectivity index and soon.Type: GrantFiled: November 29, 2019Date of Patent: March 26, 2024Assignee: INSTITUTE OF MEDICINAL BIOTECHNOLOGY, CHINESE ACADEMY OF MEDICAL SCIENCESInventors: Yanping Li, Zhuorong Li, Zonggen Peng, Xinbei Jiang, Yixuan Wang, Jianrui Li, Jiali Tan
-
Patent number: 11925650Abstract: The present invention provides an antibacterial chemical compound, its manufacturing method and its use thereof which acts as antibacterial agents being useful for treating a disease or condition characterized by infectious disease, such as gastroenteritis and invasive non-typhoidal Salmonellosis, and also providing a new therapeutic option for patients infected by the bacteria with the resistance to antibiotics.Type: GrantFiled: March 4, 2022Date of Patent: March 12, 2024Assignees: NATIONAL TAIWAN UNIVERSITY, NATIONAL YANG MING CHIAO TUNG UNIVERSITYInventors: Hao-Chieh Chiu, Chung-Wai Shiau
-
Patent number: 11925637Abstract: This invention is related to the field of PCSK9 biology and the composition and methods of use of small organic compounds as ligands for modulation of PCSK9 biological activity. In particular, the invention provides compositions of small organic compounds that modulate circulating levels of low density lipoproteins by altering the conformation of the protein PCSK9. Binding these small organic compound ligands to PCSK9 alters the conformation of the protein, modifying the interaction between PCSK9 and an endogenous low density lipoprotein receptor, and can lead to reduced or increased levels of circulating LDL-cholesterol. High LDL-cholesterol levels are associated with increased risk for heart disease. Low LDL-cholesterol levels may be problematic in other conditions, such as liver dysfunction; thus, there is also utility for small organic compound ligands that can raise LDL levels.Type: GrantFiled: March 30, 2021Date of Patent: March 12, 2024Assignee: SRX Cardio, LLCInventors: Thomas E. Barta, Jonathan William Bourne, Kyle D. Monroe, Michael M. Muehlemann, Anjali Pandey, Simeon Bowers